Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05193409 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
A Phase 2 study, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT05193409 is a Phase 2 study that has completed, run by Bionomics Limited. The registered enrollment target is 151 participants.
The verdict
NCT05193409, a Phase 2 study, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
Interventions
- DRUG Placebo
- DRUG 225 mg BNC210
- DRUG 675 mg BNC210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05193409
The ClinicalTrials.gov registry entry for NCT05193409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bionomics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05193409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05193409 about?
NCT05193409 is a clinical study titled "A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder". The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
What is the current status of trial NCT05193409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2022-02-02. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT05193409?
The interventions under investigation include: Placebo (DRUG), 225 mg BNC210 (DRUG), 675 mg BNC210 (DRUG).
Who is sponsoring clinical trial NCT05193409?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.